SRC and breast cancer: Furthermore, when breast cancer cells were treated with PKA agonizts Forskolin and IBMX (3-isobutyl-1-methylxanthine), although a strong increase of p-S133-CREB was observed, p-S17-Src and p-Y419-Src remained unchanged (Supplementary Fig. 3l–n).